Barclays PLC Actinium Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 19,369 shares of ATNM stock, worth $143,330. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,369
Previous 37,716
48.65%
Holding current value
$143,330
Previous $192,000
20.83%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ATNM
# of Institutions
72Shares Held
6.65MCall Options Held
369KPut Options Held
148K-
Black Rock Inc. New York, NY1.71MShares$12.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.45MShares$10.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA596KShares$4.41 Million0.0% of portfolio
-
State Street Corp Boston, MA551KShares$4.08 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL231KShares$1.71 Million0.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $186M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...